Nevirapine

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Virustatic.

Half-lifeThis section has been translated automatically.

30 h

Pharmacodynamics (Effect)This section has been translated automatically.

Non-nucleosidal competitive inhibitor of the reverse transcriptase of HIV.

IndicationThis section has been translated automatically.

Combination therapy of HIV infection, with 2 NNRTI or PI.

Dosage and method of useThis section has been translated automatically.

Initially 200 mg/day for 2 weeks, then twice daily 400 mg/day p.o.

Undesirable effectsThis section has been translated automatically.

Allergic exanthema, fever, nausea, drowsiness, headache, muscle aches, transaminase rises.

PreparationsThis section has been translated automatically.

Viramune

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer